Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …

Objectives This study aimed to assess the prognostic importance of hyponatremia and the
effects of dapagliflozin on serum sodium in the DAPA-HF (Dapagliflozin And Prevention of …

Background Randomized controlled trials showed that sodium/glucose cotransporter-2
inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 …

Renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose cotransporter
type 2 inhibitors (SGLT2is) are two pharmacological classes that proved a remarkable …

Context Diabetic kidney disease is a major burden among diabetic patients. Sodium-
glucose cotransporter 2 inhibitors (SGLT2is) were shown to reduce renal outcomes in …

Diabetic nephropathy is the most common cause of end-stage renal disease worldwide.
Control of blood glucose and blood pressure (BP) reduces the risk of developing this …

Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of
CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D …

The role of SGLT-2 inhibitors in managing type 2 diabetes. - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

Introduction This analysis examined the baseline characteristics and clinical outcomes of
patients with chronic kidney disease (CKD) and rapid or non-rapid estimated glomerular …

Aim To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the
Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study. Materials …